Abstract
Chronic rhinosinusitis is an inflammatory disease of the nasal and sinus mucosa. While there are multiple mechanisms by which inflammation takes place, the processes can be classified as eosinophil dominant or neutrophil dominant. Eosinophil dominant inflammation can be associated with allergen exposure and local or systemic IgE production. It is characterized by Th2 cells and IL-5. Neutrophil-dominant inflammation is triggered by mucosal exposure to microorganisms. It is characterized by Th1 and IL-8. Both eosinophils and neutrophils release cellular contents that contribute to tissue damage and inflammation.
Antibiotics have been increasingly investigated for their anti-inflammatory effects. In the setting of chronic rhinosinusitis, macrolide and tetracycline antibiotics have been trialed for their anti-inflammatory properties. The anti-inflammatory mechanisms of macrolides include the downregulation of proinflammatory genes, improvement of mucociliary function, and decreased neutrophil accumulation. Observational studies provide support for a prolonged trial of macrolide therapy when conventional therapies fail, especially in patients with low serum IgE levels. Tetracyclines exert anti-inflammatory effects by decreasing inflammatory factors, decreasing neutrophil chemotaxis, and decreasing IgE production. Tetracyclines were shown in one study to decrease nasal polyp size but without any lasting symptom improvement. More research is required to establish the utility of tetracyclines in chronic rhinosinusitis. Other antibiotics with anti-inflammatory effects are trimethoprim-sulfamethoxazole and dapsone, but neither has been applied to the rhinologic setting at present.
Antibiotics have a promising role in becoming effective adjunct therapy in patients who have refractory chronic rhinosinusitis. With the evidence currently available, macrolides are a reasonable option in patients with challenging disease. More evidence is needed, however, before tetracyclines can be routinely recommended.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Barnes PJ. Pathophysiology of allergic inflammation. Immunol Rev. 2011;242(1):31–50.
Benninger MS, et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg. 2003;129(3 Suppl):S1–32.
Bachert C, et al. Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis – a GALEN study. Allergy. 2009;64(4):520–33.
Harlin SL, et al. A clinical and pathologic study of chronic sinusitis: the role of the eosinophil. J Allergy Clin Immunol. 1988;81(5 Pt 1):867–75.
Rondon C, et al. Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis. J Allergy Clin Immunol. 2007;119(4):899–905.
Carney AS, et al. Atypical nasal challenges in patients with idiopathic rhinitis: more evidence for the existence of allergy in the absence of atopy? Clin Exp Allergy. 2002;32(10):1436–40.
Wedback A, et al. Seasonal non-allergic rhinitis (SNAR)–a new disease entity? A clinical and immunological comparison between SNAR, seasonal allergic rhinitis and persistent non-allergic rhinitis. Rhinology. 2005;43(2):86–92.
Powe DG, Bonnin AJ, Jones NS. ‘Entopy’: local allergy paradigm. Clin Exp Allergy. 2010;40(7):987–97.
Van Zele T, et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol. 2004;114(4):981–3.
Krakauer T. Immune response to staphylococcal superantigens. Immunol Res. 1999;20(2):163–73.
Hatipoglu U, Rubinstein I. Anti-inflammatory treatment of chronic rhinosinusitis: a shifting paradigm. Curr Allergy Asthma Rep. 2008;8(2):154–61.
Yoon BN, et al. Induction of interleukin-8 from nasal epithelial cells during bacterial infection: the role of IL-8 for neutrophil recruitment in chronic rhinosinusitis. Mediators Inflamm. 2010;2010:813610.
Yamada T, et al. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol. 2000;14(3):143–8.
Konstan MW, Davis PB. Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev. 2002;54(11):1409–23.
Van Crombruggen K, et al. Pathogenesis of chronic rhinosinusitis: inflammation. J Allergy Clin Immunol. 2011;128(4):728–32.
Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect. 1999;1(15):1349–65.
Thomas WW 3rd, et al. Distribution of topical agents to the paranasal sinuses: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2013;3(9):691–703.
Dubin MG, et al. American Rhinologic Society member survey on “maximal medical therapy” for chronic rhinosinusitis. Am J Rhinol. 2007;21(4):483–8.
Harvey RJ, Wallwork BD, Lund VJ. Anti-inflammatory effects of macrolides: applications in chronic rhinosinusitis. Immunol Allergy Clin North Am. 2009;29(4):689–703.
Wallwork B, et al. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope. 2006;116(2):189–93.
Videler WJ, et al. Lack of efficacy of long-term, low-dose azithromycin in chronic rhinosinusitis: a randomized controlled trial. Allergy. 2011;66(11):1457–68.
Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther. 2008;117(3):393–405.
Cervin A. The anti-inflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitis. Acta Otolaryngol. 2001;121(1):83–92.
MacLeod CM, et al. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv Ther. 2001;18(2):75–82.
Suzuki H, et al. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med. 1997;182(2):115–24.
Nakano T, et al. Roxithromycin reinforces epithelial defence function in rabbit trachea. Acta Otolaryngol Suppl. 1998;538:233–8.
Sugiura Y, Ohashi Y, Nakai Y. Roxithromycin stimulates the mucociliary activity of the Eustachian tube and modulates neutrophil activity in the healthy guinea pig. Acta Otolaryngol Suppl. 1997;531:34–8.
Ikeda K, Wu D, Takasaka T. Inhibition of acetylcholine-evoked Cl-currents by 14-membered macrolide antibiotics in isolated acinar cells of the guinea pig nasal gland. Am J Respir Cell Mol Biol. 1995;13(4):449–54.
Rhee CS, et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. Ann Otol Rhinol Laryngol. 2000;109(5):484–7.
Aoshiba K, Nagai A, Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother. 1995;39(4):872–7.
Chin AC, et al. Anti-inflammatory benefits of tilmicosin in calves with Pasteurella haemolytica-infected lungs. Am J Vet Res. 1998;59(6):765–71.
Wang T, Donahoe PK, Zervos AS. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science. 1994;265(5172):674–6.
Haruna S, et al. A study of poor responders for long-term, low-dose macrolide administration for chronic sinusitis. Rhinology. 2009;47(1):66–71.
Song Y, Bai W, Ji W. An empirical study of treating chronic sinusitis with low dose Roxithromycin. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009;23(8):357–8, 363.
Cervin A, et al. One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery: clinical outcome and effects on mucociliary parameters and nasal nitric oxide. Otolaryngol Head Neck Surg. 2002;126(5):481–9.
Katsuta S, et al. Therapeutic effect of roxithromycin on chronic sinusitis with nasal – polyps clinical, computed tomography, and electron microscopy analysis. Nihon Jibiinkoka Gakkai Kaiho. 2002;105(12):1189–97.
Kimura N, et al. Clinical effect of low-dose, long-term roxithromycin chemotherapy in patients with chronic sinusitis. Acta Med Okayama. 1997;51(1):33–7.
Moriyama H, et al. Evaluation of endoscopic sinus surgery for chronic sinusitis: post-operative erythromycin therapy. Rhinology. 1995;33(3):166–70.
Kita H, Takezawa H. Long-term low dose erythromycin and roxithromycin therapy for chronic sinusitis. Practica Otologica Kyoto. 1995;84(Suppl):62–9.
Minami T, Kubo N, Kumazawa H, et al. Long-term low dose roxithromycin therapy for chronic sinusitis. Practica Otologica Kyoto. 1995;88:1229–36.
Hashiba M, Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol Suppl. 1996;525:73–8.
Kikuchi S, Suzaki H, Aoki A, et al. Clinical effect of long-term low-dose erythromycin therapy for chronic sinusitis. Practica Otologica Kyoto. 1991;84:41–7.
Soler ZM, et al. Antimicrobials and chronic rhinosinusitis with or without polyposis in adults: an evidenced-based review with recommendations. Int Forum Allergy Rhinol. 2013;3(1):31–47.
Fokkens, WJ, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;(23): p. 3 p preceding table of contents, 1–298.
Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res. 2011;63(2):102–7.
Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90(5):520–30.
d’Ortho MP, et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem. 1997;250(3):751–7.
Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev. 2004;9(1):63–79.
Rohde LE, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99(23):3063–70.
Stetler-Stevenson WG, Liotta LA, Kleiner Jr DE. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993;7(15):1434–41.
D’Agostino P, et al. Tetracycline inhibits the nitric oxide synthase activity induced by endotoxin in cultured murine macrophages. Eur J Pharmacol. 1998;346(2–3):283–90.
Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol. 1978;70(1):51–5.
Elewski BE, et al. In vivo suppression of neutrophil chemotaxis by systemically and topically administered tetracycline. J Am Acad Dermatol. 1983;8(6):807–12.
Joks R, Durkin HG. Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs. Pharmacol Res. 2011;64(6):602–9.
Joks R, et al. Tetracycline-mediated IgE isotype-specific suppression of ongoing human and murine IgE responses in vivo and murine memory IgE responses induced in vitro. Int Immunol. 2010;22(4):281–8.
Kuzin II, et al. Tetracyclines inhibit activated B cell function. Int Immunol. 2001;13(7):921–31.
Sommer JU, et al. In vitro effects of doxycycline on inflammatory cytokines and gelatinases in chronic rhinosinusitis. In Vivo. 2012;26(3):369–74.
Van Zele T, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125(5):1069–76.e4.
Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258–65.
Kloppenburg M, et al. The influence of tetracyclines on T cell activation. Clin Exp Immunol. 1995;102(3):635–41.
Tilley BC, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med. 1995;122(2):81–9.
O’Dell JR, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum. 2001;44(10):2235–41.
Ciancio S, Ashley R. Safety and efficacy of sub-antimicrobial-dose doxycycline therapy in patients with adult periodontitis. Adv Dent Res. 1998;12(2):27–31.
Roberts DE, Curd JG. Sulfonamides as antiinflammatory agents in the treatment of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(10):1590–3.
Suematsu M, et al. Sulfasalazine and its metabolites attenuate respiratory burst of leukocytes–a possible mechanism of anti-inflammatory effects. J Clin Lab Immunol. 1987;23(1):31–3.
Stegeman CA, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994;120(1):12–7.
White ES, Lynch JP. Pharmacological therapy for Wegener’s granulomatosis. Drugs. 2006;66(9):1209–28.
Grunwald MH, Amichai B. Dapsone - the treatment of infectious and inflammatory diseases in dermatology. Int J Antimicrob Agents. 1996;7(3):187–92.
Chang DJ, et al. Dapsone in rheumatoid arthritis. Semin Arthritis Rheum. 1996;25(6):390–403.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Liu, C.C., Smith, T.L., Rudmik, L. (2015). Oral Antibiotics as Anti-inflammatories. In: Batra, P., Han, J. (eds) Practical Medical and Surgical Management of Chronic Rhinosinusitis. Springer, Cham. https://doi.org/10.1007/978-3-319-16724-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-16724-4_13
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-16723-7
Online ISBN: 978-3-319-16724-4
eBook Packages: MedicineMedicine (R0)